Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Utility of Fluoroestradiol F18 PET/CT in Metastatic Breast Cancer Patients With ER-Positive and HER2-Negative Primary Lesions After Progression on First Line Hormonal Therapy

NCT05068726 is registered in ClinicalTrials.gov with GE Healthcare as lead sponsor.

NCT NCT05068726
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05068726 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Utility of Fluoroestradiol F18 PET/CT in Metastatic Breast Cancer Patients With ER-Positive and HER2-Negative Primary Lesions After Progression on First Line Hormonal Therapy
Lead sponsor
GE Healthcare
Phase
Observational
Overall status
Terminated
Start date
January 5, 2023
Completion date
June 1, 2024
Enrollment
51 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer